Azitra, Inc. Announces Q3 2026 Results and Provides Business Updates
BRANFORD, Conn., Nov. 12, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today reported financial results for the quarter ended September 30, 2026, and provided a business update.
Q3 2026 and Recent Business HighlightsAnnounced revitalizing results from ex vivo study of ATR-COSF demonstrating ability to reduce fine lines and improve elasticity in human skinReported breakthrough repeat dose and anti-wrinkle ex vivo results for ATR-COSF program,